{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:22:41Z","timestamp":1783416161011,"version":"3.54.6"},"posted":{"date-parts":[[2026,2,13]]},"group-title":"In Review","reference-count":47,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,1,29]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  Despite therapeutic advances, relapse remains the leading cause of death in patients with acute myeloid leukemia (AML). Growth factor signaling controls AML survival, proliferation, relapse, and chemotherapy resistance. Here, we studied heparan sulfate proteoglycans, a class of molecules that bind growth factors via their heparan sulfate chains to change their signaling ability. Heparan sulfate-growth factor interactions are controlled by the addition of sulfate groups catalyzed by heparan sulfotransferases, such as those encoded by\n                  <italic>HS2ST1<\/italic>\n                  and\n                  <italic>HS6ST1<\/italic>\n                  . Using AML patient cohort analyses, we demonstrate that increased\n                  <italic>HS6ST1<\/italic>\n                  expression is associated with worse survival and increased relapse risk for AML patients harboring\n                  <italic>KMT2A<\/italic>\n                  -rearrangements. Using cell line derived xenografts, we show that AML cells depleted of\n                  <italic>HS2ST1<\/italic>\n                  , but not\n                  <italic>HS6ST1<\/italic>\n                  , have increased bone marrow leukemic burden. Further, AML cells depleted of\n                  <italic>HS6ST1<\/italic>\n                  are more sensitive to cytarabine than Control cells, suggesting that\n                  <italic>HS6ST1<\/italic>\n                  regulates AML chemotherapy resistance. Heparan sulfate antagonism with surfen synergized with cytarabine to further support AML cell death compared to cytarabine alone. Mechanistically, we demonstrate that\n                  <italic>HS6ST1<\/italic>\n                  depletion in AML cells reduces TGF-\u03b21-mediated signaling, which diminishes cell survival upon cytarabine treatment. Together, our data show that\n                  <italic>HS6ST1<\/italic>\n                  promotes AML cell chemotherapy resistance by supporting TGF-\u03b21 signaling.\n                <\/p>","DOI":"10.21203\/rs.3.rs-8725671\/v1","type":"posted-content","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:24:47Z","timestamp":1770985487000},"source":"Crossref","is-referenced-by-count":0,"title":["HS6ST1 regulates acute myeloid leukemia chemotherapy resistance via TGF-\u03b21 signaling"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-1347","authenticated-orcid":false,"given":"Christina","family":"Termini","sequence":"first","affiliation":[{"name":"Fred Hutch Cancer Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1923-1813","authenticated-orcid":false,"given":"Kelsey","family":"Woodruff","sequence":"additional","affiliation":[{"name":"Fred Hutch Cancer Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diya","family":"Patel","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5097-0652","authenticated-orcid":false,"given":"Jack","family":"Peplinski","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicollette","family":"Setiawan","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9812-2262","authenticated-orcid":false,"given":"Matthew","family":"Hagen","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6276-4423","authenticated-orcid":false,"given":"Soheil","family":"Meshinchi","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"5","key":"ref1","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.tips.2024.03.005","article-title":"AML treatment: conventional chemotherapy and emerging novel agents","volume":"45","author":"Forsberg M","year":"2024","unstructured":"Forsberg M, Konopleva M. AML treatment: conventional chemotherapy and emerging novel agents. Trends in Pharmacological Sciences. 2024;45(5):430\u201348.","journal-title":"Trends in Pharmacological Sciences"},{"issue":"12","key":"ref2","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki K","year":"2021","unstructured":"Sasaki K, Ravandi F, Kadia TM, DiNardo CD, Short NJ, Borthakur G, et al. De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. 2021;127(12):2049\u201361.","journal-title":"Cancer"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40364-025-00786-y","article-title":"Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies","volume":"13","author":"Zehtabcheh S","year":"2025","unstructured":"Zehtabcheh S, Soleimani Samarkhazan H, Asadi M, Zabihi M, Parkhideh S, Mohammadi MH. Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies. Biomark Res. 2025;13(1):73.","journal-title":"Biomark Res"},{"issue":"9","key":"ref4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41408-021-00557-6","article-title":"Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements","volume":"11","author":"Issa GC","year":"2021","unstructured":"Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, et al. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J. 2021;11(9):162.","journal-title":"Blood Cancer J"},{"key":"ref5","author":"Sobas MA","unstructured":"Sobas MA, Turki AT, Ramiro AV, S\u00e1nchez AH, Elicegui JM, Gonz\u00e1lez T, et al. Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance. haematol [Internet]. 2025 Nov 6 [cited 2026 Jan 15]; Available from: https:\/\/haematologica.org\/article\/view\/12972"},{"issue":"1","key":"ref6","first-page":"46","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian HM","year":"2025","unstructured":"Kantarjian HM, DiNardo CD, Kadia TM, Daver NG, Altman JK, Stein EM, et al. Acute myeloid leukemia management and research in 2025. CA A Cancer J Clinicians. 2025;75(1):46\u201367.","journal-title":"CA A Cancer J Clinicians"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.2147\/OTT.S191621","article-title":"Mechanisms of drug resistance in acute myeloid leukemia","volume":"12","author":"Zhang J","year":"2019","unstructured":"Zhang J, Gu Y, Chen B. Mechanisms of drug resistance in acute myeloid leukemia. OTT. 2019;Volume 12:1937\u201345.","journal-title":"OTT"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ijc.34684","article-title":"The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia","volume":"154","author":"Allert C","year":"2024","unstructured":"Allert C, M\u00fcller-Tidow C, Blank MF. The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia. Intl Journal of Cancer. 2024;154(2):197\u2013209.","journal-title":"Intl Journal of Cancer"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12964-023-01282-2","article-title":"The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways","volume":"21","author":"Bakhtiyari M","year":"2023","unstructured":"Bakhtiyari M, Liaghat M, Aziziyan F, Shapourian H, Yahyazadeh S, Alipour M, et al. The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways. Cell Commun Signal. 2023;21(1):252.","journal-title":"Cell Commun Signal"},{"issue":"9","key":"ref10","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/ijc.33908","article-title":"Microenvironment and drug resistance in acute myeloid leukemia: Do we know enough?","volume":"150","author":"Ganesan S","year":"2022","unstructured":"Ganesan S, Mathews V, Vyas N. Microenvironment and drug resistance in acute myeloid leukemia: Do we know enough? Intl Journal of Cancer. 2022;150(9):1401\u201311.","journal-title":"Intl Journal of Cancer"},{"issue":"12","key":"ref11","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1007\/s10439-008-9575-z","article-title":"Control of Growth Factor Networks by Heparan Sulfate Proteoglycans","volume":"36","author":"Forsten-Williams K","year":"2008","unstructured":"Forsten-Williams K, Chu CL, Fannon M, Buczek-Thomas JA, Nugent MA. Control of Growth Factor Networks by Heparan Sulfate Proteoglycans. Ann Biomed Eng. 2008;36(12):2134\u201348.","journal-title":"Ann Biomed Eng"},{"issue":"7","key":"ref12","doi-asserted-by":"crossref","first-page":"a004952","DOI":"10.1101\/cshperspect.a004952","article-title":"Heparan Sulfate Proteoglycans","volume":"3","author":"Sarrazin S","year":"2011","unstructured":"Sarrazin S, Lamanna WC, Esko JD. Heparan Sulfate Proteoglycans. Cold Spring Harbor Perspectives in Biology. 2011;3(7):a004952\u2013a004952.","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3389\/fendo.2018.00483","article-title":"Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression","volume":"9","author":"Nagarajan A","year":"2018","unstructured":"Nagarajan A, Malvi P, Wajapeyee N. Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression. Front Endocrinol. 2018;9:483.","journal-title":"Front Endocrinol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"778752","DOI":"10.3389\/fonc.2021.778752","article-title":"Heparan Sulfate Biosynthesis and Sulfation Profiles as Modulators of Cancer Signalling and Progression","volume":"11","author":"Marques C","year":"2021","unstructured":"Marques C, Reis CA, Viv\u00e8s RR, Magalh\u00e3es A. Heparan Sulfate Biosynthesis and Sulfation Profiles as Modulators of Cancer Signalling and Progression. Front Oncol. 2021;11:778752.","journal-title":"Front Oncol"},{"issue":"12","key":"ref15","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1369\/0022155412464972","article-title":"Heparan Sulfate Biosynthesis: Regulation and Variability","volume":"60","author":"Kreuger J","year":"2012","unstructured":"Kreuger J, Kjell\u00e9n L. Heparan Sulfate Biosynthesis: Regulation and Variability. J Histochem Cytochem. 2012;60(12):898\u2013907.","journal-title":"J Histochem Cytochem"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"C849","DOI":"10.1152\/ajpcell.00085.2022","article-title":"Spatiotemporal diversity and regulation of glycosaminoglycans in cell homeostasis and human disease","volume":"322","author":"Basu A","year":"2022","unstructured":"Basu A, Patel NG, Nicholson ED, Weiss RJ. Spatiotemporal diversity and regulation of glycosaminoglycans in cell homeostasis and human disease. American Journal of Physiology-Cell Physiology. 2022;322(5):C849\u201364.","journal-title":"American Journal of Physiology-Cell Physiology"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev-biochem-060713-035314","article-title":"Demystifying Heparan Sulfate\u2013Protein Interactions","volume":"83","author":"Xu D","year":"2014","unstructured":"Xu D, Esko JD. Demystifying Heparan Sulfate\u2013Protein Interactions. Annu Rev Biochem. 2014;83(1):129\u201357.","journal-title":"Annu Rev Biochem"},{"issue":"15","key":"ref18","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1111\/febs.14967","article-title":"Proteoglycans and glycosaminoglycans as regulators of cancer stem cell function and therapeutic resistance","volume":"286","author":"Vitale D","year":"2019","unstructured":"Vitale D, Kumar Katakam S, Greve B, Jang B, Oh E, Alaniz L, et al. Proteoglycans and glycosaminoglycans as regulators of cancer stem cell function and therapeutic resistance. FEBS J. 2019;286(15):2870\u201382.","journal-title":"FEBS J"},{"issue":"8","key":"ref19","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1111\/cas.14539","article-title":"HS2ST1-dependent signaling pathways determine breast cancer cell viability, matrix interactions, and invasive behavior","volume":"111","author":"Vijaya Kumar A","year":"2020","unstructured":"Vijaya Kumar A, Br\u00e9zillon S, Untereiner V, Sockalingum GD, Kumar Katakam S, Mohamed HT, et al. HS2ST1-dependent signaling pathways determine breast cancer cell viability, matrix interactions, and invasive behavior. Cancer Sci. 2020;111(8):2907\u201322.","journal-title":"Cancer Sci"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ccell.2023.11.008","article-title":"B3GALT6 promotes dormant breast cancer cell survival and recurrence by enabling heparan sulfate-mediated FGF signaling","volume":"42","author":"Sreekumar A","year":"2024","unstructured":"Sreekumar A, Lu M, Choudhury B, Pan T chi, Pant DK, Lawrence-Paul MR, et al. B3GALT6 promotes dormant breast cancer cell survival and recurrence by enabling heparan sulfate-mediated FGF signaling. Cancer Cell. 2024;42(1):52\u201369.e7.","journal-title":"Cancer Cell"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1083\/jcb.200610086","article-title":"Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis","volume":"177","author":"Fuster MM","year":"2007","unstructured":"Fuster MM, Wang L, Castagnola J, Sikora L, Reddi K, Lee PHA, et al. Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis. The Journal of Cell Biology. 2007;177(3):539\u201349.","journal-title":"The Journal of Cell Biology"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood.2020010447","article-title":"Syndecan-2 enriches for hematopoietic stem cells and regulates stem cell repopulating capacity","volume":"139","author":"Termini CM","year":"2022","unstructured":"Termini CM, Pang A, Li M, Fang T, Chang VY, Chute JP. Syndecan-2 enriches for hematopoietic stem cells and regulates stem cell repopulating capacity. Blood. 2022;139(2):188\u2013204.","journal-title":"Blood"},{"issue":"23","key":"ref23","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1182\/blood-2010-12-325522","article-title":"Disruption of heparan sulfate proteoglycan conformation perturbs B-cell maturation and APRIL-mediated plasma cell survival","volume":"117","author":"Reijmers RM","year":"2011","unstructured":"Reijmers RM, Groen RWJ, Kuil A, Weijer K, Kimberley FC, Medema JP, et al. Disruption of heparan sulfate proteoglycan conformation perturbs B-cell maturation and APRIL-mediated plasma cell survival. Blood. 2011;117(23):6162\u201371.","journal-title":"Blood"},{"issue":"25","key":"ref24","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood.2023022736","article-title":"Heparan sulfates and heparan sulfate proteoglycans in hematopoiesis","volume":"143","author":"Piszczatowski RT","year":"2024","unstructured":"Piszczatowski RT, B\u00fclow HE, Steidl U. Heparan sulfates and heparan sulfate proteoglycans in hematopoiesis. Blood. 2024;143(25):2571\u201387.","journal-title":"Blood"},{"issue":"32","key":"ref25","doi-asserted-by":"crossref","first-page":"17490","DOI":"10.1021\/acs.analchem.5c02338","article-title":"Quantitative HILIC-Q-TOF-MS Analysis of Glycosaminoglycans and Non-reducing End Carbohydrate Biomarkers via Glycan Reductive Isotopic Labeling","volume":"97","author":"Basu A","year":"2025","unstructured":"Basu A, Archer-Hartmann S, Chopra P, Taherzadeh Ghahfarrokhi M, Dong X, Patel NG, et al. Quantitative HILIC-Q-TOF-MS Analysis of Glycosaminoglycans and Non-reducing End Carbohydrate Biomarkers via Glycan Reductive Isotopic Labeling. Anal Chem. 2025;97(32):17490\u2013500.","journal-title":"Anal Chem"},{"issue":"15","key":"ref26","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1111\/febs.14967","article-title":"Proteoglycans and glycosaminoglycans as regulators of cancer stem cell function and therapeutic resistance","volume":"286","author":"Vitale D","year":"2019","unstructured":"Vitale D, Kumar Katakam S, Greve B, Jang B, Oh E, Alaniz L, et al. Proteoglycans and glycosaminoglycans as regulators of cancer stem cell function and therapeutic resistance. The FEBS Journal. 2019;286(15):2870\u201382.","journal-title":"The FEBS Journal"},{"key":"ref27","author":"Li S","year":"2023","unstructured":"Li S, Sampson C, Liu C, Piao H long, Liu HX. Integrin signaling in cancer: bidirectional mechanisms and therapeutic opportunities. Cell Commun Signal. 2023;21(1):266."},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-024-01899-w","article-title":"Therapeutic advances of targeting receptor tyrosine kinases in cancer","volume":"9","author":"Tomuleasa C","year":"2024","unstructured":"Tomuleasa C, Tigu AB, Munteanu R, Moldovan CS, Kegyes D, Onaciu A, et al. Therapeutic advances of targeting receptor tyrosine kinases in cancer. Sig Transduct Target Ther. 2024;9(1):201.","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1021\/acsptsci.9b00093","article-title":"The Emerging Role of Adhesion GPCRs in Cancer","volume":"3","author":"Gad AA","year":"2020","unstructured":"Gad AA, Balenga N. The Emerging Role of Adhesion GPCRs in Cancer. ACS Pharmacol Transl Sci. 2020;3(1):29\u201342.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-017-0416-0","article-title":"Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia","volume":"10","author":"Hackl H","year":"2017","unstructured":"Hackl H, Astanina K, Wieser R. Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia. J Hematol Oncol. 2017;10(1):51.","journal-title":"J Hematol Oncol"},{"issue":"35","key":"ref31","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.0805862105","article-title":"Surfen, a small molecule antagonist of heparan sulfate","volume":"105","author":"Schuksz M","year":"2008","unstructured":"Schuksz M, Fuster MM, Brown JR, Crawford BE, Ditto DP, Lawrence R, et al. Surfen, a small molecule antagonist of heparan sulfate. Proc Natl Acad Sci USA. 2008;105(35):13075\u201380.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"111027","DOI":"10.1016\/j.cellsig.2023.111027","article-title":"The roles and mechanisms of TGFB1 in acute myeloid leukemia chemoresistance","volume":"116","author":"Liang X","year":"2024","unstructured":"Liang X, Zhou J, Li C, Wang H, Wan Y, Ling C, et al. The roles and mechanisms of TGFB1 in acute myeloid leukemia chemoresistance. Cellular Signalling. 2024;116:111027.","journal-title":"Cellular Signalling"},{"key":"ref33","author":"Wang Czhu","year":"2023","unstructured":"Wang C zhu, Zhang Z qi, Zhang Y, Zheng L feng, Liu Y, Yan A ting, et al. Comprehensive characterization of TGFB1 across hematological malignancies. Sci Rep. 2023;13(1):19107."},{"issue":"6","key":"ref34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/10245332.2017.1402455","article-title":"TGF-\u03b21 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells","volume":"23","author":"Schelker RC","year":"2018","unstructured":"Schelker RC, Iberl S, M\u00fcller G, Hart C, Herr W, Grassinger J. TGF-\u03b21 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells. Hematology. 2018;23(6):337\u201345.","journal-title":"Hematology"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"101242","DOI":"10.1016\/j.drup.2025.101242","article-title":"A quiescence-like\/TGF-\u03b21-specific CRISPRi screen reveals drug uptake transporters as secondary targets of kinase inhibitors in AML","volume":"81","author":"Rahimian E","year":"2025","unstructured":"Rahimian E, Koochak M, Traikov S, Schroeder M, Brilloff S, Sch\u00e4fer S, et al. A quiescence-like\/TGF-\u03b21-specific CRISPRi screen reveals drug uptake transporters as secondary targets of kinase inhibitors in AML. Drug Resistance Updates. 2025;81:101242.","journal-title":"Drug Resistance Updates"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood.2020010447","article-title":"Syndecan-2 enriches for hematopoietic stem cells and regulates stem cell repopulating capacity","volume":"139","author":"Termini CM","year":"2022","unstructured":"Termini CM, Pang A, Li M, Fang T, Chang VY, Chute JP. Syndecan-2 enriches for hematopoietic stem cells and regulates stem cell repopulating capacity. Blood. 2022;139(2):188\u2013204.","journal-title":"Blood"},{"issue":"13","key":"ref37","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2020008188","article-title":"Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis","volume":"137","author":"Ren Z","year":"2021","unstructured":"Ren Z, Spaargaren M, Pals ST. Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis. Blood. 2021;137(13):1713\u20138.","journal-title":"Blood"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.matbio.2023.05.005","article-title":"3-O sulfation of syndecan-1 mediated by the sulfotransferase HS3ST3a1 enhances myeloma aggressiveness","volume":"120","author":"Baert L","year":"2023","unstructured":"Baert L, Manfroi B, Quintero M, Chavarria O, Barbon PV, Clement E, et al. 3-O sulfation of syndecan-1 mediated by the sulfotransferase HS3ST3a1 enhances myeloma aggressiveness. Matrix Biol. 2023;120:60\u201375.","journal-title":"Matrix Biol"},{"issue":"29","key":"ref39","doi-asserted-by":"crossref","first-page":"18000","DOI":"10.1074\/jbc.272.29.18000","article-title":"The interaction of the transforming growth factor-betas with heparin\/heparan sulfate is isoform-specific","volume":"272","author":"Lyon M","year":"1997","unstructured":"Lyon M, Rushton G, Gallagher JT. The interaction of the transforming growth factor-betas with heparin\/heparan sulfate is isoform-specific. J Biol Chem. 1997;272(29):18000\u20136.","journal-title":"J Biol Chem"},{"issue":"5","key":"ref40","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/molecules22050713","article-title":"Heparan Sulphate and the TGF-\u03b2 Cytokine Superfamily","volume":"22","author":"Rider CC","year":"2017","unstructured":"Rider CC, Mulloy B. Heparin, Heparan Sulphate and the TGF-\u03b2 Cytokine Superfamily. Molecules. 2017;22(5):713.","journal-title":"Molecules"},{"issue":"4","key":"ref41","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/hep.27658","article-title":"Activation of the transforming growth factor-\u03b2\/SMAD transcriptional pathway underlies a novel tumor\u2010promoting role of sulfatase 1 in hepatocellular carcinoma","volume":"61","author":"Dhanasekaran R","year":"2015","unstructured":"Dhanasekaran R, Nakamura I, Hu C, Chen G, Oseini AM, Seven ES, et al. Activation of the transforming growth factor-\u03b2\/SMAD transcriptional pathway underlies a novel tumor\u2010promoting role of sulfatase 1 in hepatocellular carcinoma. Hepatology. 2015;61(4):1269\u201383.","journal-title":"Hepatology"},{"issue":"2","key":"ref42","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/jcp.1041520226","article-title":"Transforming growth factor-beta 1 is a heparin-binding protein: identification of putative heparin-binding regions and isolation of heparins with varying affinity for TGF-beta 1","volume":"152","author":"McCaffrey TA","year":"1992","unstructured":"McCaffrey TA, Falcone DJ, Du B. Transforming growth factor-beta 1 is a heparin-binding protein: identification of putative heparin-binding regions and isolation of heparins with varying affinity for TGF-beta 1. J Cell Physiol. 1992;152(2):430\u201340.","journal-title":"J Cell Physiol"},{"issue":"21","key":"ref43","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1182\/blood.V124.21.4372.4372","article-title":"Impairment of AML Engraftment to the Bone Marrow Niche Following Inhibition of TGF-Beta Signaling","volume":"124","author":"Hamilton A","year":"2014","unstructured":"Hamilton A, Foster K, Bonnet D. Impairment of AML Engraftment to the Bone Marrow Niche Following Inhibition of TGF-Beta Signaling. Blood. 2014;124(21):4372\u20134372.","journal-title":"Blood"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"e69734","DOI":"10.7554\/eLife.69734","article-title":"Dysregulated heparan sulfate proteoglycan metabolism promotes Ewing sarcoma tumor growth","volume":"11","author":"Vasileva E","year":"2022","unstructured":"Vasileva E, Warren M, Triche TJ, Amatruda JF. Dysregulated heparan sulfate proteoglycan metabolism promotes Ewing sarcoma tumor growth. eLife. 2022;11:e69734.","journal-title":"eLife"},{"issue":"11","key":"ref45","doi-asserted-by":"crossref","first-page":"11973","DOI":"10.1096\/fj.201802610RR","article-title":"Surfen-mediated blockade of extratumoral chondroitin sulfate glycosaminoglycans inhibits glioblastoma invasion","volume":"33","author":"Logun MT","year":"2019","unstructured":"Logun MT, Wynens KE, Simchick G, Zhao W, Mao L, Zhao Q, et al. Surfen-mediated blockade of extratumoral chondroitin sulfate glycosaminoglycans inhibits glioblastoma invasion. The FASEB Journal. 2019;33(11):11973\u201392.","journal-title":"The FASEB Journal"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1158\/1535-7163.MCT-18-0104","article-title":"A Unique Nonsaccharide Mimetic of Heparin Hexasaccharide Inhibits Colon Cancer Stem Cells via p38 MAP Kinase Activation","volume":"18","author":"Boothello RS","year":"2019","unstructured":"Boothello RS, Patel NJ, Sharon C, Abdelfadiel EI, Morla S, Brophy DF, et al. A Unique Nonsaccharide Mimetic of Heparin Hexasaccharide Inhibits Colon Cancer Stem Cells via p38 MAP Kinase Activation. Molecular Cancer Therapeutics. 2019;18(1):51\u201361.","journal-title":"Molecular Cancer Therapeutics"},{"issue":"11","key":"ref47","doi-asserted-by":"crossref","first-page":"e20212552","DOI":"10.1084\/jem.20212552","article-title":"A glycan-based approach to cell characterization and isolation: Hematopoiesis as a paradigm","volume":"219","author":"Piszczatowski RT","year":"2022","unstructured":"Piszczatowski RT, Schwenger E, Sundaravel S, Stein CM, Liu Y, Stanley P, et al. A glycan-based approach to cell characterization and isolation: Hematopoiesis as a paradigm. Journal of Experimental Medicine. 2022;219(11):e20212552.","journal-title":"Journal of Experimental Medicine"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8725671\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8725671\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T08:43:36Z","timestamp":1783413816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8725671\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":47,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-8725671\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,2,13]]},"subtype":"preprint"}}